National Institutes of Health (NIH)
National Institute of Biomedical Imaging and
National Cancer Institute (NCI)
National Eye Institute (NEI)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute on Drug Abuse (NIDA)
National Institute of Environmental Health Sciences (NIEHS)
National Institute of Neurological Disorders and Stroke (NINDS)
Bioengineering Research Partnerships (U01 Clinical Trial Optional)
U01 Research Project – Cooperative Agreements
Reissue of PAR-16-116
93.286, 93.867, 93.113, 93.273, 93.279, 93.394, 93.395, 93.853, 93.865, 93.399, 93.393
This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems. The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine. Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project. The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.
November 7, 2017
April 8, 2018
May 8, 2018, September 13, 2018, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
October-November 2018, February-March 2019.
January 2019, May 2019
April 2019, July 2019
January 8, 2019
Required Application Instructions
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
I. Funding Opportunity Description
Section II. Award Information
Section III. Eligibility Information
Section IV. Application and Submission Information
Section V. Application Review Information
Section VI. Award Administration Information
Section VII. Agency Contacts
Section VIII. Other Information
The goal of a Bioengineering Research Partnership (BRP) is to drive the development and speed the adoption of promising tools and technologies that can address important biomedical problems for which insufficient or no solutions exist. The use of engineering principles is encouraged to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need. A synergistic partnership between engineering and the life, physical, and computational sciences is also encouraged, where the unique skills of each discipline combine to enhance our understanding of life science processes or the practice of medicine.
The purpose of this FOA is to encourage BRP applications that: 1) establish a robust engineering solution to a problem in biomedical research or the practice of medicine; 2) develop a strategic alliance of multidisciplinary partners based on a well-defined leadership plan; and 3) realize a specific endpoint within 5-10 years based on a detailed plan with a timeline and quantitative milestones.
For many years, the NIH has recognized that the application of principles and techniques from physics, mathematics, chemistry, computer sciences, and engineering can be used to solve significant biomedical problems, leading in turn to new understanding of biological processes, novel products, and innovative tools to improve health. To address this, three distinct program announcements, the BRP, the Bioengineering Research Grant (BRG), and the Exploratory/Developmental Bioengineering Research Grant (EBRG), encourage and support the use of bioengineering and other physical scientific methods to solve problems in biological and biomedical research and clinical practice. These three announcements cover the spectrum of activity, from earliest stage (EBRG) to development of collaborative projects (BRG) to a team-partnership structure with a specific timeframe and milestones (BRP). To facilitate a multidisciplinary approach, these announcements include review criteria that emphasize ways in which a project may incorporate bioengineering principles to drive new understanding or changes in clinical practice.
The primary objective of this FOA is to encourage basic, applied, or clinical bioengineering solutions to unmet needs in biological or biomedical research and clinical practice that can enhance the capabilities of end-users to improve our understanding of life science processes or the practice of medicine within 5 – 10 years. A BRP may bring together new or existing technologies to form creative solutions that have the potential to be widely adopted and improve human health. To deliver practical solutions within this timeframe, applicants are encouraged to use a design-directed research strategy with well-defined end goal(s) and intermediate, quantitative milestones. Goals may include, but are not limited to, establishing proof of concept, pre-commercial prototype production, licensure, release of software packages, designs or models, demonstrating the biological effectiveness of engineered constructs, elucidating the structural and functional relevance of biomolecules or tissues, first-in-human testing, or starting the investigational device exemption or investigational new drug process.
A second key objective is to encourage collaborations and partnerships among allied quantitative and biomedical disciplines. The value of strategic partnerships is well supported by the literature of both economics and science and technology policy, which documents greater success at research and development by groups that work in strategic alliances, often involving multiple institutions, compared to those working separately. In addition to the benefits to be derived from the research, the collaborations and partnerships can create opportunities for trans-disciplinary communication and training of a new generation of scientists who are capable of interacting across traditional technical boundaries. A Partnership typically consists of two to six partners from multiple institutions or multiple departments from the same institution, with each partner bringing critical strengths to the project. The team may require experience in technology development, appropriate model systems for validation, human factors research, regulatory approval, project management or commercialization to realize and disseminate a robust solution. Potential beneficiaries should be active participants in the partnership from the beginning, to provide assurance that proposed solutions will meet community needs. Partnerships with companies that have relevant expertise or may eventually engage in future commercialization or with organizations that can test and disseminate technologies are encouraged under the BRP program. Each PD/PI or collaborator is expected to provide substantive contributions to the intellectual or technical aspects of the project, and should be clearly differentiated from team members who supply necessary but not unique components or services.
Funding may be requested to develop, adapt, enhance, optimize, validate, or otherwise accelerate the adoption of promising bioengineering solutions, but not for support of commercial production or later stage (Phase II or Phase III) clinical trials. The approach used does not necessarily need to be extremely novel and may be based on integrating or scaling up existing technologies in untested ways. Overall impact of these new capabilities may include but is not limited to reducing disparities in care, providing new insight into basic biological processes, promoting wellness and independent living, engineering integrated biological and physical systems, increasing access to and usability of technologies to improve quality of life, reducing cost and complexity of high-demand tools, or increasing throughput sensitivity and specificity of laboratory and clinical studies. Innovation for this program is based on a coherent plan to deliver emerging or new capabilities to end users, including through combination of proven approaches and recognizing their resources, workflow, and skills. Developing a technology is expected to require innovation, but novelty in and of itself is not a requirement. For this FOA, it is innovative to deliver a new capability to solve an unmet need. Innovation in this case is heightened by a technology that can be easily adopted into routine practice and will give users, for example biomedical researchers, healthcare professionals, or citizens, new understanding, or will change health care practice.
Projects must clearly serve the mission of one or more of the NIH Institutes or Centers (ICs) participating in this FOA. Investigators are strongly encouraged to contact the Scientific/Research contacts identified in this FOA for individual IC policies, as well as feedback on the scope and relevance of the proposed project and guidance on the development of appropriate goals and milestones. Those investigators seeking to establish proof of concept are encouraged to respond to the EBRG FOA (PA-18-286). Investigators proposing smaller team projects, tackling problems that cannot be addressed within 5 – 10 years, or that have open-ended aims, are encouraged to respond to the BRG FOA (PAR-18-206).
Institute statements of interest:
The mission of the National Cancer Institute is to reduce the burden of cancer. Toward that end it encourages applications for funding on research to gain understanding and achieve mitigations and solutions to cancer problems. Interests in understanding, mitigations, solutions, and dissemination of knowledge and methods cover: cancer basic knowledge on what it is, causes and prevention, risk factors, screening, diagnosis and staging, monitoring, prognosis, symptoms, finding care givers and treatment facilities, types of treatment, side effects, clinical trials including information for caregivers and patients, cancer drugs, complementary and alternative medicine, among other interests. More details on cancer, types, research, grants and training, news and events, and about NCI may be found at http://www.cancer.gov.
The mission of the National Eye Institute (NEI) is to conduct and support research, training, health information dissemination, and other programs with respect to blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health problems and requirements of the blind. The NEI is interested in supporting bioengineering research that advances the development of technology and therapeutics to accomplish this mission. Areas of particular interest to the NEI are: i) developing new ocular imaging instruments and methods to image function as well as structure; ii) integrating multiple imaging modalities into a single instrument; iii) creating artificial, bioengineered corneal implants; iv) creating vision prostheses; v) developing novel bioengineering approaches to drug delivery; and vi) developing new technology to provide access to visual displays (e.g., refreshable Braille for internet), navigation resources, and other assistive devices. For additional information about specific scientific programs of research interest in the NEI, please visit our home page at https://nei.nih.gov/.
The mission of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) is to conduct and support biomedical and behavioral research with respect to the prevention of alcohol abuse and the treatment of alcoholism and alcohol related health effects. Development of research or clinical tools that advance the understanding of fundamental cell and molecular biological mechanism of the deleterious effects of alcohol is encouraged. Of particular interest is the development of a discreet, accurate, wearable alcohol biosensor to support NIAAA’s mission in the arenas of research, treatment, and rehabilitation.
The mission of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating engineering with the physical and life sciences to advance basic research and medical care. One way that this is achieved is through the support of research and development of new biomedical imaging and bioengineering tools and technologies to improve the prevention, detection, treatment, and monitoring of disease. NIBIB scientific program areas that are appropriate for the BRP mechanism can be found at http://www.nibib.nih.gov/Research/ProgramAreas. NIBIB supports research from early stage technology development through first in human demonstrations and early feasibility clinical studies.
Prior to funding an application, NIBIB program staff will contact the applicant to discuss the proposed timeline and go-no go milestones and any changes suggested by the review panel or program staff. A final timeline and approved milestones will be specified in the Notice of Award. Progress toward achieving the milestones will be evaluated by NIBIB program staff. If a funded project does not meet the milestones, funding for the project may be discontinued.
The mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is to ensure that every person is born healthy and wanted, that women suffer no harmful effects from reproductive processes, and that all children have the chance to achieve their full potential for healthy and productive lives, free from disease or disability, and to ensure the health, productivity, independence, and well-being of all people through optimal rehabilitation. The NICHD is interested in supporting bioengineering research that advances the development of technology and medicine to accomplish this mission. Examples of areas of research interest include, but are not limited to: a) the development of novel technologies, both imaging and non-imaging, which accelerate the ability to safely and non-invasively assess human placental development and function in real time across pregnancy; b) pediatric specific technologies and equipment used by emergency and trauma care personnel; and c) innovations in diagnostic methods such as advanced imaging, fluid biomarkers, or genetic profiling to assess rehabilitation intervention readiness. For additional information about specific scientific programs of research interest to a Branch in the NICHD, please visit our home page at http://www.nichd.nih.gov .
NIDA's mission is to lead the Nation in bringing the power of science to bear on drug abuse and addiction. NIDA continues to support a great deal of innovative biomedical research on drug addiction and related health problems such as pain, HIV/AIDS, and obesity. The interests of NIDA also include technologies able to elucidate functional and structural changes to the brain longitudinally across the addiction trajectory. Particularly relevant topics include the development of technologies that enable investigations of glia-neuron interactions, monitoring the release of multiple types of neurotransmitters simultaneously (e.g. dopamine and serotonin), non-invasive stimulation of deep (limbic) brain areas, measuring synaptic plasticity and spine growth including silent synapses and calcium permeable AMPA receptors, monitoring and stimulating the sparse neuronal ensembles activated during drug-related behaviors, recording of individual differences and environmental influences (e.g. animal behavior in home cages, social interactions, exploration, impulsivity, novelty, reward response) to predict addictive phenotypes, and the development of new technologies that enhance prevention and treatment programs for drug addiction.
The mission of the NIEHS is to discover how the environment affects people in order to promote healthier lives. For the purposes of this FOA, NIEHS has particular interest in exploration of bioengineering concepts and biomaterials, stem cells, iPSCs, and tissue-on-chip technologies that can lead to preventive strategies. Illustrative projects include, but are not limited to: technologies leading to identification and monitoring of early biomarkers for health and disease; tools and assays designed to determine DNA repair capacity in individuals and human populations; high-throughput assays to determine genome integrity; application of biomaterials that allow improved measure of the effects of chemical exposure or stressors on stem cells; in vivo or in situ assays or tools that act as reporters of exposure – response in living organisms and can be applied to people; tools to improve determination of exposure – response and clarify the resulting short or long term physiological consequences.
For applications relevant to the mission (http://www.ninds.nih.gov/about_ninds/mission.htm) of the National Institute for Neurological Disorders and Stroke (NINDS) under this FOA:
Applications should be milestone-driven, translational engineering for development and regulatory approval of targeted, diagnostic devices (excluding neuro-imaging). Specific go/no-go milestones will be negotiated with NINDS Program staff at the time of award for inclusion in the notice of award. Applications proposing translational studies designed for pre-clinical and pilot clinical studies for therapeutic devices, specifically, should be submitted to one of the following NINDS CREATE Devices FOAs (http://www.ninds.nih.gov/funding/areas/translational_research/CREATE-Devices.htm).
Applications for NINDS proposing pre-translational, pre-clinical, investigative research projects on deliberative optimization and development of devices for impacts in neurology and neuroscience should apply through the Bioengineering Research Grants (R01) or Exploratory Bioengineering Research Grants (R21) [refer to 2018 FOAs].
NINDS will not accept applications under this announcement that include clinical trials (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-015.html). A clinical trial is a prospective biomedical or behavioral research study of human subjects designed to answer specific questions about safety, tolerability, efficacy and/or effectiveness of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions. Other human subjects research can be submitted and NINDS may decline funding of any application that includes human subjects for programmatic or administrative reasons. Applicants considering projects involving human subjects research are strongly encouraged to contact Scientific/Research staff. Applications for NINDS proposing a clinical trial must be submitted to one of the following NINDS FOAs specifically designed for clinical trials (http://www.ninds.nih.gov/research/clinical_research/index.htm#tab3-panel)
Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.
The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types.
Optional: Accepting applications that either propose or do not propose clinical trial(s)
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Application budgets are not limited but need to reflect the actual needs of the proposed project.
The scope of the proposed project should determine the project period. The maximum project period is 5 years.
NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made in response to this FOA.
Higher Education Institutions
The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:
Nonprofits Other Than Institutions of Higher Education
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.
Program Directors/Principal Investigators (PD(s)/PI(s))
All PD(s)/PI(s) must have an eRA Commons account. PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.
For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.
This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:
Applicants must obtain the SF424 (R&R) application package associated with this funding opportunity using the “Apply for Grant Electronically” button in this FOA or following the directions provided at Grants.gov.
It is critical that applicants follow the instructions in the SF424 (R&R) Application Guide, including Supplemental Grant Application Instructions except where instructed in this funding opportunity announcement to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.
For information on Application Submission and Receipt, visit Frequently Asked Questions – Application Guide, Electronic Submission of Grant Applications.
All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.
The following section supplements the instructions found in the SF424 (R&R) Application Guide and should be used for preparing an application to this FOA.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
Other Attachments: Applicants are required to include a Leadership Plan. For applications that do not utilize Multiple PDs/PIs, this item must be uploaded as a separate attachment in pdf format with a filename that corresponds to the item (Leadership Plan). For Multiple PD/PI applications, the Leadership Plan should be uploaded using the Multiple PD/PI Leadership Plan attachment on the PHS 398 Research Plan form. Applications lacking this required item will be deemed incomplete and will not be reviewed. The Leadership Plan is limited to 6 pages.
Leadership Plan: As part of the Leadership Plan, applicants are encouraged to build collaborations and partnerships among allied quantitative and biomedical disciplines. An organizational structure that clearly defines the partnership and relationships among the various components must be described in the Leadership Plan and illustrated in an organizational chart. This plan should also describe the governance and organizational structure of the leadership team and the research project, including communication plans, processes for making decisions on scientific direction, intellectual property, and procedures for resolving conflicts. The roles and administrative, technical, and scientific responsibilities for the project or program should be delineated for the PDs/PIs and other collaborators. For publications, policies to address the ordering and recognition of authors, and decisions about what material to publish, consistent with the interests of commercial partners (where applicable) should be presented. Under terms and procedures to be defined in the Leadership Plan, the partnership has the responsibility and authority to use BRP funds in the most productive way to achieve the goals defined at the time that the award is made. To accomplish these tasks, the PDs/PIs can adjust funding among BRP participants to support new partners or to reduce support to existing partners as needed. Plans for enhancing the abilities and opportunities for investigators to work across disciplinary boundaries should also be included.
All instructions in the SF424 (R&R) Application Guide must be followed.
Biographical Sketch. Indicate experience in project management as well as assessing and meeting stakeholder needs
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions:
Specific Aims: The problems to be addressed and the timeliness and appropriateness of the solution must be stated concisely. Key milestones, uniqueness of the team, and the expected outcomes of the project, if successful, should be described succinctly.
Research Strategy: As part of the Research Strategy, applicants are asked to address the following points:
Note for Applications Proposing the involvement of Human Subjects and/or Clinical Trials: Use the Research Strategy section to discuss the overall strategy, methodology, and analyses of your proposed research, but do not duplicate information collected in the PHS Human Subjects and Clinical Trial Information form. The PHS Human Subjects and Clinical Trial Information form will capture detailed study information, including eligibility criteria; inclusion of women, minorities, and children; protection and monitoring plans; and statistical design and power. You are encouraged to refer to information in the PHS Human Subjects and Clinical Trial Information form as appropriate in your discussion of the Research Strategy (e.g., see Section 2.4 Inclusion of Women, Minorities, and Children).
Significance: Briefly describe the area of bioengineering research that is the focus of the BRP. Explain why a multidisciplinary approach is needed to realize a solution. Explain how the proposed project will improve scientific knowledge, technical capability, and/or clinical practice by providing new capabilities to users. Critically evaluate existing knowledge and approaches that have been or are being applied in the area and specifically describe how the proposed BRP approach will advance the field.
Innovation: Innovation for this FOA is based on a coherent plan to deliver emerging or new capabilities to end users, including through combinations of proven approaches and recognizing their resources, workflow, and skills. Developing a technology is expected to require innovation, but novelty in and of itself is not a primary requirement. For the purpose of this FOA it is to deliver a new capability to satisfy an unmet need. Innovation in this case is heightened by a technology that can be easily adopted into routine practice and will give users, such as biomedical researchers, healthcare professionals or citizens, new understanding, or will change healthcare-related practice. Describe any novel advanced system integration..
Approach: Technical feasibility for the approach should be clearly established by preliminary results so that any risks present can be mitigated using engineering and project management principles. Comparison of performance specifications with current practice is expected, such as sensitivity, specificity, reproducibility, reliability, portability, throughput, operability by biological researchers or healthcare workers, potential research or clinical utility and cost of acquisition and operation as applicable. An integrative systems approach or a design-driven approach and their appropriateness for the proposed project should be described, including plans for collecting, analyzing, interpreting, and archiving data. Details for making the performance of technologies sufficiently selective, sensitive, or otherwise appropriate for the identified problem should be supported with quantitative benchmarks. Potential technical challenges and possible alternative approaches to achieve the aims of the project should be discussed. If the proposed BRP research is closely related to ongoing research, explain how the research activities of the BRP will complement but not overlap with the existing research. The robustness and reproducibility of preliminary results should be described along with independent validation or replication of results if available. Alternative interpretations of preliminary data, including relevant literature in support or disagreement with the results, should be described. For projects that pursue feasibility in humans, the approach should describe contact with appropriate regulatory bodies and milestones for achieving regulatory approval.
Project Milestones and Timeline: Generate a subsection in the Approach Section that addresses Milestones and a project Timeline. Include quantitative milestones, a schedule of tasks and events including responsible personnel, and/or other evaluative criteria. Projects must identify semi-annual milestones, and provide timelines highlighting dependencies among tasks. For each milestone, provide details on methods, assumptions, experimental designs, and data analysis plans (if applicable). Quantitative criteria for success in the milestones may also be used for making go/no-go decisions and this should be specified. Applicants are encouraged to discuss impediments that could require a revision to the research plan, milestones or timeline, with a discussion of alternative approaches.
Applicants for Renewals should be aware that BRP funding will not be extended past the end of the second funding award and should describe plans for sustaining the project beyond this time.
Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:
All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.
The plan should include details for sharing raw (unreduced) data with other researchers who may wish to analyze them independently, and include plans for disseminating resources. Investigators are expected to be aware of and abide by all applicable NIH guidance for sharing of research resources and data, consistent with existing laws, regulations, and policies. Please see https://grants.nih.gov/grants/policy/data_sharing/data_sharing_faqs.htm
There is no prescribed sharing approach for software produced by a project. However, reviewers will be asked to comment on the adequacy and effectiveness of plans based on their likely impact. Program staff may negotiate modifications of software sharing plans with the PD/PI before making recommendations on funding of an application.
All applications should describe plans for disseminating the techniques and technologies to end-users. The plan should complement the research and development strategy, and my involve partnership with industry, professional organizations, or community engagement.
Appendix: Do not use the Appendix to circumvent page limits. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.
When involving NIH-defined human subjects research, clinical research, and/or clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:
If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a delayed onset study record.
Study Record: PHS Human Subjects and Clinical Trials Information: All instructions in the SF424 (R&R) Application Guide must be followed.
Delayed Onset Study: All instructions in the SF424 (R&R) Application Guide must be followed.
All instructions in the SF424 (R&R) Application Guide must be followed.
Foreign (non-U.S.) institutions must follow policies described in the NIH Grants Policy Statement, and procedures for foreign institutions described throughout the SF424 (R&R) Application Guide.
See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov
Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.
Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.
Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.
Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.
This initiative is not subject to intergovernmental review.
All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Pre-award costs are allowable only as described in the NIH Grants Policy Statement.
Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.
Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.
For assistance with your electronic application or for more information on the electronic submission process, visit Applying Electronically. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Guidelines for Applicants Experiencing System Issues. For assistance with application submission, contact the Application Submission Contacts in Section VII.
All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this FOA for information on registration requirements.
The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the SF424 (R&R) Application Guide.
See more tips for avoiding common errors.
Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review, NIH. Applications that are incomplete or non-compliant will not be reviewed.
Applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.
Applicants are required to follow our Post Submission Application Materials policy.
Important Update: See NOT-OD-18-228 for updated review language for due dates on or after January 25, 2019.
Only the review criteria described below will be considered in the review process. As part of the NIH mission, all applications submitted to the NIH in support of biomedical and behavioral research are evaluated for scientific and technical merit through the NIH peer review system.
For this particular announcement, note the following:
Innovation for this FOA is based on a coherent plan to deliver new or emerging capabilities to end users, including through a combination of proven approaches and recognizing their resources, workflow, and skills. Developing a technology to solve an unmet need is expected to require this type of innovation, but novelty in and of itself is not a requirement.
Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).
For this particular announcement, note the following: A proposed Clinical Trial application may include study design, methods, and intervention that are not by themselves innovative but address important questions or unmet needs. Additionally, the results of the clinical trial may indicate that further clinical development of the intervention is unwarranted or lead to new avenues of scientific investigation.
Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.
Does the project address an important problem or a critical barrier to progress in the field? Is there a strong scientific premise for the project? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field? Will the project address a problem or critical barrier for which there is a scarcity of other solutions? If the goals of the BRP are achieved, will they provide new capabilities that will enhance biomedical research or clinical practice? Will the technological advances improve human health?
In addition, for applications proposing clinical trials: Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? For trials focusing on clinical or public health endpoints, is this clinical trial necessary for testing the safety, efficacy or effectiveness of an intervention that could lead to a change in clinical practice, community behaviors or health care policy? For trials focusing on mechanistic, behavioral, physiological, biochemical, or other biomedical endpoints, is the trial needed to advance scientific understanding?
Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project? Does the leadership team have sufficient project management experience? Does the partnership have appropriate experience with enhancing, adapting, optimizing, validating or otherwise accelerating the development and adoption of biomedical technologies? Does the team have experience assessing and meeting stakeholder needs? Will the PD(s)/PI(s) provide an appropriate level of effort to effectively lead the project, manage resources, and coordinate the partners?
In addition, for applications proposing clinical trials: With regard to the proposed leadership for the project, do the PD/PI(s) and key personnel have the expertise, experience, and ability to organize, manage and implement the proposed clinical trial and meet milestones and timelines? Do they have appropriate expertise in study coordination, data management and statistics? For a multicenter trial, is the organizational structure appropriate and does the application identify a core of potential center investigators and staffing for a coordinating center?
Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed? Will the project deliver new capabilities, taking into account end-user resources, workflow and skills? Will the proposed approaches or concepts solve current scientific or technical problems in creative ways?
In addition, for applications proposing clinical trials: Does the design/research plan include innovative elements, as appropriate, that enhance its sensitivity, potential for information or potential to advance scientific knowledge or clinical practice?
Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?
Are the BRP engineering, scientific, and clinical approaches and methods adequately developed, well-integrated, and appropriate to the aims of the project? Is the Leadership Plan clear, sound, appropriate, and practical? If partnership with industry or other organization is proposed, does this positively affect the research goals and technology dissemination?
If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of children, justified in terms of the scientific goals and research strategy proposed?
In addition, for applications proposing clinical trials: Does the application adequately address the following, if applicable:
Is the study design justified and appropriate to address primary and secondary outcome variable(s)/endpoints that will be clear, informative and relevant to the hypothesis being tested? Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Given the methods used to assign participants and deliver interventions, is the study design adequately powered to answer the research question(s), test the proposed hypothesis/hypotheses, and provide interpretable results? Is the trial appropriately designed to conduct the research efficiently? Are the study populations (size, gender, age, demographic group), proposed intervention arms/dose, and duration of the trial, appropriate and well justified?
Are potential ethical issues adequately addressed? Is the process for obtaining informed consent or assent appropriate? Is the eligible population available? Are the plans for recruitment outreach, enrollment, retention, handling dropouts, missed visits, and losses to follow-up appropriate to ensure robust data collection? Are the planned recruitment timelines feasible and is the plan to monitor accrual adequate? Has the need for randomization (or not), masking (if appropriate), controls, and inclusion/exclusion criteria been addressed? Are differences addressed, if applicable, in the intervention effect due to sex/gender and race/ethnicity?
Are the plans to standardize, assure quality of, and monitor adherence to, the trial protocol and data collection or distribution guidelines appropriate? Is there a plan to obtain required study agent(s)? Does the application propose to use existing available resources, as applicable?
Are planned analyses and statistical approach appropriate for the proposed study design and methods used to assign participants and deliver interventions? Are the procedures for data management and quality control of data adequate at clinical site(s) or at center laboratories, as applicable? Have the methods for standardization of procedures for data management to assess the effect of the intervention and quality control been addressed? Is there a plan to complete data analysis within the proposed period of the award?
Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements? Does the partnership foster trans-disciplinary communication and training opportunities across traditional scientific and technical boundaries?
In addition, for applications proposing clinical trials: If proposed, are the administrative, data coordinating, enrollment and laboratory/testing centers, appropriate for the trial proposed? Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? Are the plans to add or drop enrollment centers, as needed, appropriate? If international site(s) is/are proposed, does the application adequately address the complexity of executing the clinical trial? If multi-sites/centers, is there evidence of the ability of the individual site or center to: (1) enroll the proposed numbers; (2) adhere to the protocol; (3) collect and transmit data in an accurate and timely fashion; and, (4) operate within the proposed organizational structure?
As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.
Do the organizational structure and leadership plan of the project indicate an ability to meet the proposed goal(s) within 5 – 10 years? Does the information provided suggest an ability to effectively partner and manage multidisciplinary projects and deal with sensitive but critical go/no-go decisions in a team-based environment?
Milestones and Timeline
Are milestones associated with clear, quantitative criteria for success that allow go/no-go decisions? Are the timelines proposed for achieving the milestones realistic and inclusive of necessary steps? Would achieving all milestones in the application allow the project to achieve the end goals for the project?
Specific to applications proposing clinical trials: Is the study timeline described in detail, taking into account start-up activities, the anticipated rate of enrollment, and planned follow-up assessment? Is the projected timeline feasible and well justified? Does the project incorporate efficiencies and utilize existing resources (e.g., CTSAs, practice-based research networks, electronic medical records, administrative database, or patient registries) to increase the efficiency of participant enrollment and data collection, as appropriate? Are potential challenges and corresponding solutions discussed (e.g., strategies that can be implemented in the event of enrollment shortfalls)?
For research that involves human subjects but does not involve one of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.
For research that involves human subjects and meets the criteria for one or more of the six categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.
When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of children to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.
The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.
Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.
For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project.
For Renewals, the committee will consider the progress made in the last funding period.
For Revisions, the committee will consider the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.
As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.
Reviewers will assess whether the project presents special opportunities for furthering research programs through the use of unusual talent, resources, populations, or environmental conditions that exist in other countries and either are not readily available in the United States or augment existing U.S. resources.
Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).
Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3) Genomic Data Sharing Plan (GDS).
For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.
Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.
Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the Center for Scientific Review, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.
As part of the scientific peer review, all applications:
Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:
After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.
Information regarding the disposition of applications is available in the NIH Grants Policy Statement.
If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the NIH Grants Policy Statement.
A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the grantee’s business official.
Awardees must comply with any funding restrictions described in Section IV.5. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.
Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.
Additionally, ICs may specify any special reporting requirements for the proposed clinical trial to be included under IC-specific terms and conditions in the NoA. For example: If the proposed clinical trial has elevated risks, ICs may require closer programmatic monitoring and it may be necessary to require the awardee to provide more frequent information and data as a term of the award (e.g., to clarify issues, address and evaluate concerns, provide documentation). All additional communications and information related to programmatic monitoring must be documented and incorporated into the official project file. Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.
ClinicalTrials.gov: If an award provides for one or more clinical trials by law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain “applicable clinical trials” on the ClinicalTrials.gov Protocol Registration and Results System Information Website (https://register.clinicaltrials.gov). NIH expects registration of all trials whether required under the law or not. For more information, see http://grants.nig.gov/ClinicalTrials_fdaaa/.
Institutional Review Board or Independent Ethics Committee Approval: Grantee institutions must ensure that the application as well as all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the awardee must provide NIH copies of documents related to all major changes in the status of ongoing protocols.
Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&R) and PHS 398).
Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).
All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General and Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Grantees, and Activities. More information is provided at Award Conditions and Information for NIH Grants.
Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights law. This means that recipients of HHS funds must ensure equal access to their programs without regard to a person’s race, color, national origin, disability, age and, in some circumstances, sex and religion. This includes ensuring your programs are accessible to persons with limited English proficiency. HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.
For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA. HHS provides general guidance to recipients of FFA on meeting their legal obligation to take reasonable steps to provide meaningful access to their programs by persons with limited English proficiency. Please see https://www.hhs.gov/civil-rights/for-individuals/special-topics/limited-english-proficiency/index.html. The HHS Office for Civil Rights also provides guidance on complying with civil rights laws enforced by HHS. Please see http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html; and https://www.hhs.gov/civil-rights/for-providers/laws-regulations-guidance/index.html. Recipients of FFA also have specific legal obligations for serving qualified individuals with disabilities. Please see http://www.hhs.gov/ocr/civilrights/understanding/disability/index.html. Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.html or call 1-800-368-1019 or TDD 1-800-537-7697. Also note it is an HHS Departmental goal to ensure access to quality, culturally competent care, including long-term services and supports, for vulnerable populations. For further guidance on providing culturally and linguistically appropriate services, recipients should review the National Standards for Culturally and Linguistically Appropriate Services in Health and Health Care at http://minorityhealth.hhs.gov/omh/browse.aspx?lvl=2&lvlid=53.
Cooperative Agreement Terms and Conditions of Award
The following special terms of award are in addition to, and not in lieu of, otherwise applicable OMB administrative guidelines, HHS grant administration regulations at 45 CFR Parts 74 and 92 (Part 92 is applicable when State and local Governments are eligible to apply), and other HHS, PHS, and NIH grant administration policies.
The administrative and funding instrument used for this program will be the cooperative agreement an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the awardees is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the awardees for the project as a whole, although specific tasks and activities may be shared among the awardees and the NIH as defined below.
The PD(s)/PI(s) will have the primary responsibility for:
The Program Director/Principal Investigator will have the primary responsibility for: defining objectives and approaches, and to plan, conduct, analyze, and publish results, interpretations, and conclusions of their studies. Awardees are responsible for identifying specific, rigorous milestones and objective success criteria, quantitative where appropriate.
Awardees will retain custody of and have primary rights to the data and software developed under these awards, subject to Government rights of access consistent with current HHS, PHS, and NIH policies.
Awardees agree to participate at least once a year in progress meetings that may be called and organized by IC staff.
Awardees are responsible for pursuing patent protection.
Awardees are responsible for providing progress reports that include experimental design, including assumptions that underlie the design of the experiments, the results of the investigations, interpretations of the results, and whether or not milestones have been met or exceeded. In cases when IC staff request raw data, awardees agree to provide those data.
Awardees agree to communicate study reports, meeting minutes, and associated data packages if applicable, letters and other forms of communications with regulatory agencies, and other authorities if applicable.
NIH staff will have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:
An Institute program officer serving as Project Scientist will have substantial scientific-programmatic involvement during conduct of this activity, through technical assistance, advice and coordination above and beyond the normal program stewardship role in grant awards, as described below. The IC Project Scientist will provide input on the milestones and make decisions regarding their finalization. The program officer will be responsible for technical monitoring of the project, such as approval of changes in experimental approaches, objectives, milestones and timelines; assessing progress against specified milestones and stated project timelines, as well as for recommending if further funds should be released to the project. However, the role of the Project Scientist will be to facilitate and not to direct the activities. It is anticipated that decisions on major changes will be reached by consensus between the PD(s)/PI(s) and the Project Scientist, and that Institute staff will be given the opportunity to offer input into this process. The Project Scientist may provide assistance by accessing Institute-supported resources and services.
Additionally, an Institute program director will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice.
Areas of Joint Responsibility include:
Clarifying, negotiating and finalizing the milestones and timelines as well as attending any project-specific meetings called by the Project Scientist to discuss and resolve issues that may arise during the project period, which affect project performance and/or progress.
Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to arbitration. An Arbitration Panel composed of three members will be convened. It will have three members: a designee of the award recipient(s) chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual awardee. This special arbitration procedure in no way affects the awardee's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulations 42 CFR Part 50, Subpart D and HHS regulations 45 CFR Part 16.
A final progress report, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement.
The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for awardees of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All awardees of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over $25,000. See the NIH Grants Policy Statement for additional information on this reporting requirement.
We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.
eRA Service Desk (Questions regarding ASSIST, eRA Commons
registration, submitting and tracking an application, documenting system
problems that threaten submission by the due date, post submission issues)
Finding Help Online: https://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)
(Questions regarding application instructions and process, finding NIH grant
Email: GrantsInfo@nih.gov (preferred method of contact)
NIH scientific contacts listed at the following website should be contacted for answers to questions about scientific issues: http://www.nibib.nih.gov/research-funding/bioengineering-contacts
General questions about this funding opportunity announcement can be addressed to:
Šeila Selimovic, Ph.D.
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
6707 Democracy Blvd, Ste 200, MSC 5477
Bethesda, MD 20892
Eileen Bradley, Ph.D.
Center for Scientific Review (CSR)
NIH financial contacts listed at the following web site should be contacted for answers to questions about financial issues: http://www.nibib.nih.gov/Funding/Bioengineering/Contacts
Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.
Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75.
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.